PhoenixMD Selected to Participate in 2017 Biocom's Global Life Science Conference 2017

JANUARY 16, 2017 - Phoenix Molecular Designs was selected to participate in Biocom's Global Life Science Partnering Conference 2017, which will be held on March 1-2, 2017. Our CEO Dr. Sandra Dunn will be in attendance to showcase our important work to fight  Breast Cancer.

Biocom's Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives and business development professionals from leading pharmaceutical and biotech companies. The conference includes case study presentations, individual company presentations, one-one-one meetings, and numerous networking opportunities. 

The 10 companies best suited to pitch to prospective pharmaceutical partners will receive free admission (a $2000 USD value), as well as coaching and mentoring from an MNE experienced consultant in advance of the Conference. They are looking for drug development biotech firms that have game changing technologies targeting an unmet medical need, with secure IP, eye-popping data, and completed animal studies towards Proof-of-Concept and/or Phase 1 Human Clinical trials. The participating companies will have the unique opportunity to engage in the San Diego BIOCOM Coaching and Mentoring Program.

The Consulate of Canada in San Diego with support from IRAP and ISED is currently recruiting companies interested in receiving coaching and mentoring in advance of the BIOCOM Global Pharma Partnering Conference which is held on March 1-2, 2017. PhoenixMD is one of the 10 companies selected in this years competition based on their competitive edge and their ability to meet the stringent requirements for the Program.

For more information about Biocom and/or the 2017 Global Life Science Partnering Conference visit

PhoenixMD Advances Into Top 10 of Small Business BC Awards for Innovation of the Year

December 13, 2016 - PhoenixMD Advances into Top 10 of Small Business BC Award for Innovation of the Year 2016 and we could not be more thrilled! We would like to thank everyone who voted for us, as well as Small Business BC for giving us this amazing opportunity.

Stay tuned for updates!

Take a look at all the Top 10 Finalists of all Categories here

New Window decal outside phoenix Molecular designs at the richmond LABORATORIES #SBBCAWARDS

New Window decal outside phoenix Molecular designs at the richmond LABORATORIES #SBBCAWARDS


The Honorable Linda Reid, Richmond East MLA, Visits the PhoenixMD Laboratories

November 25, 2016 - PhoenixMD was humbled at the chance to invite the Honorable Linda Reid, MLA: East Richmond, to the PhoenixMD labs in Richmond. Linda has been in office since 1991 and has continued to represent Richmond East ever since - making her the longest serving MLA in the current parliament!

We are happy to call Linda our friend and are proud to have her support for the work we are doing at PhoenixMD. Here are some pictures of her visit.

Pictured: The Hon. Linda Reid beside Dr. Sandra Dunn at the PhoenixMD Labs in Richmond.

Pictured: The Hon. Linda Reid beside Dr. Sandra Dunn at the PhoenixMD Labs in Richmond.

Pictured: The Hon. Linda Reid, Dr. Aarthi Jayanthan and Dr. Sandra Dunn at the PhoenixMD Labs in Richmond.

Pictured: The Hon. Linda Reid, Dr. Aarthi Jayanthan and Dr. Sandra Dunn at the PhoenixMD Labs in Richmond.

Pictured: The Hon. Linda Reid beside Dr. Sandra Dunn at the PhoenixMD Labs in Richmond.

Pictured: The Hon. Linda Reid beside Dr. Sandra Dunn at the PhoenixMD Labs in Richmond.

PhoenixMD Selected For The Canadian Technology Accelerator Program In The Silicon Valley, California

November 8, 2016 - It is with great pleasure to announce the selection of PhoenixMD for the Canadian Technology Accelerator (CTA) program in Silicon Valley, California. The CTA San Francisco program gives Canadian companies the opportunity to gain global recognition and insight into the competitive life science market. San Francisco/Silicon Valley is home to one of the largest life science hubs and markets in the U.S. which grants unparalleled access to global multi-nationals, investors and venture financers. PhoenixMD was selected among hundreds of Canadian companies to go to California to access the resources required to accelerate our growth in the U.S. and the world! PhoenixMD will have the opportunity to be introduced to the U.S./Global market, Fortune 500 companies, investors and strategic partners.

The acceptance into the CTA program will bring PhoenixMD one step close to finding a cure for cancer. 

PhoenixMD attends the 6th Annual Outsourcing in Clinical Trials Canada 2016

October 5/6, 2016 - Dr. Aarthi Jayanthan and Dr. My-my Huynh were fortunate to attend the 6th Annual Outsourcing in Clinical Trials Canada 2016 (AOCTC) at the Westin Wall Center in Vancouver, BC. The two-day conference focused on the best strategies used to optimize clinical trials and the various methods used to deal with difficulties that may be encountered along the way. The AOCTC was very informative and will give PhoenixMD a starting edge when planning and performing optimal clinical trial operations. Troubleshooting strategies were also discussed which will also allow PhoenixMD to outsource clinical trials in a time efficient manner. 

To learn more about the Annual Outsourcing in Clinical Trials Canada click here

PhoenixMD Validated as a Top Investor-Ready Company in the Pacific Northwest at Cascadia Venture Forum 2016

October 5, 2016 - PhoenixMD was selected to present in the Cascadia Venture Forum 2016 held in Vancouver on Oct 4, 2016.  PhoenixMD was pre-screened and validated as one of the top investor-ready companies in the Pacific Northwest (British Columbia, Washington and Oregon). Dr. Sandra Dunn presented among angel inventors, venture capitalists, industry players and other ecosystem members in this premier seed investment forum for life science start-ups.

We would like to thank the Cascadia Venture Forum for this amazing opportunity and look forward to participating in future programs.

PhoenixMD attends the 21st Annual Michael Cuccione Gala

September 24, 2016 - PhoenixMD attended the 21st Annual Michael Cuccione Gala to support childhood cancer research. The Michael Cuccione Foundation has supported PhoenixMD since the beginning and continues to be a loyal supporter of our cancer research today. 

To learn more about The Michael Cuccione Foundation and their mission in childhood cancers click here

Dr. Sandi Dunn (CEO + Founder) pictured along side Dr. My-My Huynh (Research Scientist) and Luisa D'Amato (Research Technician) at the 21st Annual Michael Cuccione Foundation Gala 
Dr. Sandi Dunn (CEO + Founder) and Dr. Nick Sharp (Chief of Operations) pictured alongside Dr. My-My Huynh (Research Scientist) and Luisa D'Amato (Research Technician) at the 21st Annual Michael Cuccione Foundation Gala 



PhoenixMD selected to present at "Dose of the Valley" in San Francisco

February 19, 2016 — Phoenix Molecular Designs was selected to present at Dose of the Valley in San Francisco on February 9th and 10th, 2016. Dose of the Valley is a two-day program organized by the C100, BDC Venture Capital and the Canadian Consulate in San Francisco. The annual by invitation-only event connects Canada’s most promising life science companies from biopharma, medical device and health IT sectors through roundtable discussions, industry-led workshops, one-on-one mentorship, an investor/partnering pitch session, and a networking reception. Out of 60 applicants across Canada, only 20 were selected to attend by a high-level review committee.

Silicon Valley in San Francisco represents a global hub for life sciences. With a significant presence of pharmaceutical companies, health care providers, and venture capital, this region holds tremendous opportunity for Canadian companies. This is a unique opportunity for innovative Canadian companies to engage with valuable industry contacts, gain visibility, and develop productive relationships within this top global innovation ecosystem.

“As a leader in cancer therapeutics, we are very pleased to have been selected to join this program and present innovative Canadian-developed technology,” says Sandra Dunn, CEO, PhoenixMD. The Dose of the Valley event connected PhoenixMD with large pharmaceutical companies, and facilitated one-on-one meetings. It provided exposure to venture capital and private investment opportunities. Finally, the Dose of the Valley created partnership opportunities with companies based in the United States and Canada.

A Day for Science and Compassion: Vancouver Consular Circle & Phoenix Molecular Designs

June 9th, 2015 – The Vancouver Consular Circle (VCC) had a ‘meeting of the minds’ at Phoenix Molecular Diagnostics. The VCC has representatives from several different parts of the world and this meet was a great opportunity to increase awareness about the various kinds of breast cancer, its cure and Phoenix’s role in it.

The work you are doing at Phoenix is exceptional Sandi. You are an inspiration to us all. I am proud to know you.
— Juliette Potter, Consulate General of Britain

At this informational lunch session, Dr. Sandra Dunn (Sandi) and her team gave the VCC a tour of the lab space where the cutting edge research happens. This was followed by a presentation, which was extremely informational and empowering. The presentation took them through the spectacular results of over 8 years of cancer research and study. It also outlined the evolution of cancer treatments, from traditional chemotherapy to targeted treatments, which is what PhoenixMD specializes in. The VCC was excited to learn that we are in the process of creating a personalized drug for Triple Negative Breast Cancer, the deadliest kind of breast cancer, which will be far gentler than chemotherapy while being more effective and potent. PhoenixMD’s strategy is to create the drug as well as the companion diagnostic test along with it. This will enable the drug to be given out to only those individuals who test positive for this specific kind of Breast Cancer. This makes the treatment highly targeted and personalized. The drug compound is currently being optimized and will undergo stringent testing before its release.

Top Insights from the session:

 1.    Breast Cancer is a global issue – 1.7 Million women are diagnosed every year and half a million women die due to this disease every year.

2.   Unfortunately, breast cancer is on the rise. It is reported to go up by ~50% by 2030.

3.   Despite the media, the cause of breast cancer is not typically due to a bad gene that is inherited.  BRCA-1 mutations only account for ~5% of breast cancers. Lifestyle plays a role in Breast cancer. Eat healthy products that do not contain toxins, drink in moderation and exercise. However, the most important cause for Breast Cancer is DNA damage, which cannot be anticipated.

4.   There are 4 different subtypes of Breast Cancer- some worse than the other. Each of them needs to be treated differently.

5.   Early detection is still the best way to ensure recovery and rehabilitation. How can we ensure the cancer is detected early on?

a.    Regular Mammography Screening: The current guidelines for Canada recommend a mammogram once every two years for women over the age of 50. For those with a family history, an earlier scan may be provided by talking to your family doctor.

b.    Self-Exam: There is nothing more important than self-examination, lumps. This is extremely important, as you may detect something that even the mammogram may miss.

To test their knowledge on all that they had learned, there was a fun quiz, and they did extremely well! We continued the riveting discussion over a ‘healthy’ lunch from Peqish.

What we hope they took away is this: The need of the hour is advocacy. People need to band together, especially us women. We need to not only be aware but also build this awareness in our communities. We don’t all have to be scientists; we all have strengths that we can use to further this cause. We all need to be a part of this journey and do what we can to help.

It was a very beneficial visit and we are glad that the VCC will be a part of our journey towards finding an effective, targeted treatment for Triple Negative Breast Cancer.